Your browser is not supported. Please upgrade to a modern browser in order to use all the features of the UKHC web application: Firefox | Chrome | Microsoft Edge
Skip to main content
close menu
close menu

Search UK HealthCare

Table test

  • Events






    B. Mark Evers, MD
    Director, Markey Cancer Center
    University of Kentucky

    General Session I: Assessment and Treatment of Solid Tumors


    Keynote 1: Role of ETCTN in fostering cancer research in Appalachian Kentucky:  Challenges and opportunities.

    Charles Kunos, MD, PhD
    Investigational Drug Branch, National Cancer Institute
    Washington, DC

    1. Discuss ETCTN sponsored clinical trial opportunities for Appalachian communities


    Precision Treatment of Neuroendocrine Tumors

    Aman Chauhan, MD
    Assistant Professor of Medicine
    University of Kentucky

    Erica L. Takimoto, DO
    Gynecologic oncologist
    Norton Cancer Institute
    Louisville, Kentucky

    1. List new treatment options for neuroendocrine tumors
    2. Provide patient specific recommendations for managing neuroendocrine tumors


    Assessment And Treatment Of Solid Tumors Overview And Discussion

    Session I Speakers

    Moderated by:

    Discuss the various treatments of solid tumors and how it impacts patient care





    Workshop 1 (Participants pick one)

    1. Novel Surgical Strategies in GI Malignancies

    Michael Cavnar, MD
    Assistant Professor of Surgery
    University of Kentucky

    Joseph Kim, MD
    Chief of Surgical Oncology
    University of Kentucky

    1. Describe the role of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of GI cancers
    2. Discuss the role intraarterial chemotherapy to target metastatic liver lesions
    3. Implementing a Germline Precision Medicine Program

    Brook Phillips, MD
    Medical Oncologist
    St. Elizabeth Healthcare
    Edgewood, KY

    Dan Flora, MD
    Medical Oncologist 
    St. Elizabeth Healthcare
    Edgewood, KY

    1. Describe the role of CYP2D6 genotyping in the use of tamoxifen
    2. Discuss implementation strategies for common drug metabolizing agents and their use in oncology
    3. New Therapies for AML, Targeting FLT3 and IDH Mutations

    Reshma Ramlal, MD
    Assistant Professor of Medicine
    University of Kentucky

    1. Describe the place in therapy of hypomethylating agents, sorafenib, ivosidenib, and enasidenib
    2. Recognize and manage adverse effects associated with these agents
    3. Hot Topics: Gene Expression Prognostic Assays in Breast Cancer and Markers of Intratumoral Heterogeneity

    Rachel Stewart, DO, PhD
    Assistant Professor of Pathology and Laboratory Medicine
    University of Kentucky

    Therese Bocklage, MD
    Professor of Pathology and Laboratory Medicine
    University of Kentucky

    1. Discuss recent results from TailorRx trial
    2. Describe gene expression assays to assess prognosis in breast cancer
    3. Identify methods to assess intratumoral heterogeneity and its impact of clinical diagnostics


    Lunch with Ongoing Clinical Trials Poster Session



    Workshop 2 (Participants pick one)

    Implementing a CAR T-Cell Therapeutic Program

    Gerhardt Hildebrandt, MD, FACP
    Professor of Medicine,  
    Division Chief, Hematology and Blood Marrow Transplantation
    University of Kentucky

    Amber Lawson, PharmD
    Assistant Professor, College of Pharmacy
    University of Kentucky

    Jennifer Christian
    Division of Hematology and Blood Marrow Transplantation
    Administrative Coordinator
    UK HealthCare

    1. Describe challenges and strategies to overcome them when implementing a CAR T-cell program
    2. Managing Combination Immunotherapies

    John Villano, MD, PhD
    Professor of Medicine
    University of Kentucky

    Rachael Morgan, PharmD
    Hematology/Oncology Clinical Pharmacist
    UK HealthCare

    1. Describe common indications and adverse effects associated with combination immunotherapies and their management
    2. Panel: Inherited Cancer Syndromes

    Rachel C. Miller, MD
    Associate Professor of Obstetrics and Gynecology
    University of Kentucky

    Peng Wang, MD,
    Assistant Professor of Medicine
    University of Kentucky

    Justine Cooper Pickarski, MS
    Genetic Counselor Supervisor
    University of Kentucky

    1. Discuss recent updates for germline testing recommendations for ovarian, prostate and pancreas cancer
    2. Identify appropriate candidates for germline testing
    3. Describe mechanisms for genetic counselor referrals
    4. Novel Advances in Next Generation Sequencing

    Shulin Zhang, MD, PhD
    Professor of Pathology and Medicine
    University of Kentucky

    a)  Describe the recent advances in next generation sequencing technology

    Role of NGS testing in Precision Management of Hematological Malignancies

    Ranjana Arora, MD, MPH. FCAP
    Assistant Professor of Pathology and Laboratory Medicine
    Medical Director, Molecular Hematology Services
    University of Kentucky

    1. Discuss recent technology advances integral to precision medicine
    2. Explain and interpret NGS of hematological malignancies




    General Session II:  Treatment Advances in Hematological Malignancies


    Treatment Advances in CAR T-cells

    Hayder Saeed, MD

    Assistant Professor of Medicine

    University of Kentucky


    Jacob Hodskins, MD, MS


    Owensboro Health Medical Group

    Owensboro, Kentucky


    1. Explain a difficult relapsed case of diffuse large B cell lymphoma
    2. Describe recent clinical advances in CAR T-cell therapy


    Keynote 2: The Future is Finally Here: Targeted Therapy in the Treatment of Acute Myeloid Leukemia


    Eytan M. Stein, MD

    Hematologic Oncologist

    Memorial Sloan Kettering Cancer Center

    New York, NY


    1. Discuss place in therapy for targeted therapies for AML


    Treatment Advances in Hematological Malignancies Overview and Discussion

    Session II Speakers


    Moderated by:

    Firas Badin, MD


    BHMG Hematology and Oncology

    Lexington, Kentucky


    Review the advance treatment of hematological malignancies, the benefits and its impact on patients and their care